Background: Syringolymphoid hyperplasia with alopecia is considered to be a rare variant of cutaneous T-cell lymphoma. Current therapy for cutaneous T-cell lymphoma limited to the skin favors topical treatment, chemo-, and photochemotherapy. Case Report: We report on a 52-year-old patient presenting with disseminated, reddish-brown scaly papules on both soles and erythematous papules with alopecia on his thighs. First skin lesions arose 5 years ago and subsequently a continuous progression was noted. Finally, the patient was severely limited due to pressure-induced pain on the soles. Topical glucocorticosteroids, local PUVA bath therapy, and systemic interferon-α administration failed to improve skin lesions. Thus, a local radiotherapy with 60Co γ-rays was administered. A total dose of 30 Gy was delivered in 2-Gy fractions over a 3-week period. Clinically, there was a complete regression of irradiated skin lesions. Conclusion: Though there is limited experience regarding the therapy of syringolymphoid hyperplasia with alopecia, radiotherapy has to be considered in recalcitrant cases.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.